A Phase II/III Randomized Trial of Veliparib or Placebo in Combination with Adjuvant Temozolomide in Newly Diagnosed Glioblastoma with MGMT Promoter Hypermethylation
Alliance A071102 is permanently closed to new patient registration (Step 1) effective October 15, 2018.
